Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 October 2024 | Story André Damons | Photo Supplied
Dr Mutshidzi Mulondo
Dr Mutshidzi Mulondo, academic in the Division of Public Health within the Faculty of Health Sciences at UFS.

Dr Mutshidzi Mulondo, an academic in the Division of Public Health within the Faculty of Health Sciences, at the University of the Free State (UFS), has won a prestigious Global Health Award at the margins of the Global Health Summit in London, the UK.

Dr Mulondo, who is a Novartis Reimagining Healthcare Scholar and a Visiting Scholar at the Beaver College of Health Sciences at Appalachian State University, in the US, was a finalist in two categories: ‘Mental Health and Well-being’ and ‘Rising Star’. She won the Zenith Global Health Award under the category ‘Mental Health and Well-being’. The awards ceremony took place on 28 September and saw health professionals and academics gather in Europe for the auspicious occasion.

“This nomination and selection are an honour that bears testament to my dedication and commitment to SDG 3 (Good Health and Well-being). I hope this win serves as inspiration to young people, particularly to young women in academia and in the sciences,” says Dr Mulondo. The awards are an esteemed platform renowned for celebrating global recognition and excellence, fostering collaboration and innovation in the healthcare sector. They further serve as recognition for contributions made through education, research and/or technology and innovation.

Eco-anxiety

Dr Mulondo, who was invited to attend the summit for the first time, joined a panel of speakers on the session theme ‘mental health and climate change’ where she shared insights on eco-anxiety – the intersection of climate change and mental health which was coined by Albrecht as the chronic fear of environmental change.

Research by the McKinsey Health Institute, says Dr Mulondo, a fellow of the UFS Emerging Scholar Accelerator Programme (ESAP) and member of the UNESCO AG for Women in Science, indicates that more than 75% of young people are pessimistic about the future due to climate change. Most young people in the activism frontlines experience activist burn-out from consistent campaigning, while others experience eco-gaslighting from those who feel climate change is a non-issue. These negative emotions are further exacerbated by young people’s exposure to social media of constant images and conversations about environmental degradation due to climate change.

Pact for the future

Dr Mulondo flew to London from New York after participating in the 79th United Nations General Assembly’s Summit of the Future and Science Summit, as well as the New York Climate Week. She further provided insights into the adoption of the Pact for the Future which was adopted during the Summit of the Future. “With only 17% of the Sustainable Development Goals (SDGs) targets on track to be achieved by 2030, 18% stagnant and 17% regressed to pre-2015 when the goals were first adopted (SDG Report 2024), Mental Health still remains among 10 global health issues to track according to the World Health Organisation (WHO),” says Dr Mulondo.

“The Summit of the Future, which is regarded as a once-in-a-generation high-level event,” she continues, “was aimed at establishing a new global consensus to safeguard the present and future generations. Current challenges such as health pandemics, political unrest, and climatic changes were factored into discussions to keep apace with the changing world in the adoption of the Pact for the Future”.

Recommendations and mitigation efforts should focus on encouraging those experiencing eco-anxiety to focus on joining collective action efforts (i.e. campaigns to clean ocean and beach environments (etc,) so that they feel they are doing something towards saving the planet. “This will help alleviate the feelings of ‘hopelessness’ which some experience from not knowing what to do about the environmental degradation. Furthermore, intergenerational collaboration is necessary for young people to voice their concerns and innovative ideas on the issue, while the older generation listens and further shares their lived wisdom. Ultimately, collective support (Ubuntu) is what is needed as part of the mitigation efforts,” concludes Dr Mulondo.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept